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Abstract The interaction of cardiac Na+^Ca2+ exchange
(NCX1) with caveolin proteins was investigated in sarcolemmal
vesicles. Western blots of sarcolemmal vesicles revealed the
presence of caveolin-1, -2, and -3. NCX1 co-fractionated more
closely with caveolin-3 than caveolin-1 on sucrose density
gradients. NCX1 has five possible caveolin-binding motifs and
NCX1 co-precipitated specifically with caveolin-3. Molecular
sieve column chromatography indicated that this co-precipitation
was not due to incomplete solubilization of lipid raft micro-
domains. Cholesterol chelation in vesicles decreased NCX1
transport activity and caveolin-3 co-precipitation. NCX1 may
play a role in caveolar transmembrane signaling in addition to its
role in excitation^contraction coupling. ß 2002 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
The cardiac Na^Ca2 exchanger (NCX1) moves Ca2
across the myocyte sarcolemma and helps regulate myocardial
contractility. NCX1 transports Ca2 into the cell during sys-
tole (backward mode) and Ca2 out of the cell during diastole
(forward mode). Because it plays a role in myocardial Ca2
homeostasis, NCX1 could be an important regulator for sig-
naling factors involved in raising or lowering inotropic activ-
ity of the heart. For many types of cells, the signaling factors
are now known to be concentrated in microdomains called
caveolae [1,2]. Caveolae composition is cell speci¢c and char-
acteristically they contain isoforms of the known caveolin
proteins (caveolin-1, -2, and -3). Caveolins bind to and regu-
late the activity of many components of receptor signaling
pathways through their ‘sca¡olding’ domain [1,2].
Recent animal and human clinical studies have reported an
increase or upregulation of NCX1 in heart failure (HF) [3^5],
although reports linking NCX1 function to HF are still rare
[6]. The muscle speci¢c isoform, caveolin-3, has also been
shown to increase in HF [7]. The increase in caveolin-3 and
sarcolemmal caveolae in HF is thought to enhance nitric ox-
ide signaling [7]. In endothelial cells, nitric oxide synthase co-
puri¢ed with caveolin-1 and NCX1 in sucrose density gra-
dients [8]. However, the NCX1 protein was observed in all
fractions and therefore a clear association of NCX1 with cav-
eolin protein in endothelial cells has not been established.
There are no previous reports of NCX1 association with cav-
eolins in cardiac myocytes.
In the present study, we examined the interaction of NCX1
protein with caveolin proteins in cardiac sarcolemmal vesicles.
Sarcolemmal vesicles, which are prepared from myocardial
tissue composed of myocytes as well as endothelial cells and
smooth muscle cells, contained caveolin-1, -2, and -3. Our
data demonstrate that NCX1 co-precipitates with the muscle
speci¢c isoform, caveolin-3. It is possible that some sarcolem-
mal NCX1 transporters may play a role in caveolar trans-
membrane signaling, in addition to its better-understood
role in excitation^contraction coupling.
2. Materials and methods
2.1. Preparation of bovine cardiac sarcolemmal (BSl) vesicles
BSl vesicles were prepared as described [9]. The ¢nal vesicle product
was suspended in 160 mM NaCl, 20 mM 3-[N-morpholino]propane-
sulfonic acid (MOPS)/Tris, pH 7.4. Vesicles were maintained at
370‡C prior to use.
2.2. Preparation of Sepharose bead immobilized antibodies and
immunoprecipitation
NCX1 antibody (A⁄nity Bioreagents, Golden, CO, USA), caveo-
lin-3 antibody (Transduction Laboratories, Lexington, KY, USA) and
non-immunogenic IgG were coupled to CNBr 4B Sepharose beads
(Sigma, St. Louis, MO, USA) per the manufacturer’s instructions.
Beads were extensively washed after coupling and equilibrated in ex-
traction bu¡er consisting of 60 mM octylglucoside detergent, 160 mM
NaCl, and 20 mM MOPS adjusted to a ¢nal pH of 7.4 with Tris.
BSl vesicles (4 mg) were thawed, pelleted by centrifugation, and
resuspended in extraction bu¡er (5 ml). The resuspended mixture
was maintained on ice for 30 min with periodic vortex mixing. The
detergent extract was subjected to centrifugation (160 000Ug for 15
min). Detergent-solubilized proteins were recovered from the super-
natant fraction and mixed with bead-immobilized NCX1 antibody,
caveolin-3 antibody or non-immunogenic IgG (40 Wl beads/ml extract)
and allowed to gently mix in a rotating mixer at 4‡C for 18 h. Beads
were extensively washed with several changes of extraction bu¡er. The
¢nal bead pellets were resuspended in sodium dodecyl sulfate^polyac-
rylamide gel electrophoresis reducing sample bu¡er and boiled for
6 min prior to electrophoretic procedures.
2.3. Sucrose density gradient membrane fractionation
Ventricular tissue membranes [9] were applied to a 5^35% discon-
tinuous sucrose gradient as previously described [10]. 2 ml gradient
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fractions were collected and concentrated by 10% trichloroacetic acid
precipitation prior to electrophoretic analysis.
2.4. Molecular sieve column chromatography
BSl vesicle protein was solubilized as in immunoprecipitation
studies and subjected to molecular sieve column chromatography
by Sephadex G150-120 as previously described [11]. Column perfor-
mance (fractionation by size) was determined using a commercially
available kit (Gel Filtration Calibration Kit, Pharmacia, Piscataway,
NJ, USA).
2.5. NCX1 transport assay
NCX1 activity was determined as previously described [9]. Three
second transport time points were performed on at least three di¡er-
ent vesicle preparations. All points are the result of triplicate deter-
minations.
2.6. Chemicals and reagents
Unless otherwise noted, all reagents were obtained from Sigma, St.
Louis, MO, USA.
3. Results and discussion
3.1. Caveolin-binding motifs in NCX1
The sca¡olding domain of caveolin is the region of the
protein that associates with or binds to other proteins seques-
tered in caveolae [1]. Two related caveolin-binding motifs, i.e.
motifs present on caveolin-associated proteins that bind to the
sca¡olding region, have been described. The two motifs are:
PXPXXXXP and PXXXXPXXP, where P is aromatic amino
acids Trp (W), Phe (F) or Tyr (Y), and X is any amino acid
[1]. To associate directly with caveolins, a protein must con-
tain this motif. A scan of NCX1 primary amino acid sequence
indicated the presence of ¢ve potential caveolin-binding mo-
tifs located at amino acids 171^179, 223^231, 224^231, 620^
627, and 875^883 (Fig. 1). Interestingly, three of these motifs
are located at regions of the protein which have special sig-
ni¢cance. Two are nestled within the transporter’s endogenous
exchange inhibitory peptide domain, a region of NCX1 in-
volved in regulation of transport [9,12]. A third at amino
acids 620^627 is an alternative splicing exon found in NCX1
but not other exchanger isoforms [13]. Because the caveolin
sca¡olding domain, which associates with the binding motif,
is located at or near the cytoplasmic face of the plasma mem-
brane, it is unlikely that the motifs at amino acids 171^178 or
875^883 on the extracellular side of the membrane are actual
caveolin-binding sites.
3.2. The presence of caveolin protein in cardiac sarcolemmal
vesicle preparations
Western blots of BSl vesicle proteins (15 Wg) were probed
with antibodies against NCX1, caveolin-1, -2, and -3 (Fig. 2a).
Fig. 1. Predicted location of NCX1 caveolin-binding motifs. The hy-
dropathy plot model of NCX1 is based upon topological analysis
[17]. Transmembrane regions are represented by shaded cylinders
and extramembranal loops are black lines. Endogenous exchange in-
hibitory peptide (XIP) is shown as a black box. Arrows designate
the approximate location of the NCX1 caveolin-binding motifs.
Two (amino acids 171^179 and 875^883) are modeled to be in
transmembrane helices near the external face of the sarcolemma
membrane. Amino acids 223^231, 224^231, and 620^627 are all
modeled to exist on the protein’s large cytoplasmic loop. The ¢rst
two segments actually overlap within the endogenous XIP domain
and the third segment (620^627) correlates with a cardiac speci¢c
splice variant.
Fig. 2. Western blot analysis of caveolin and NCX1 proteins. Western blot (immunoblot) analysis of sarcolemma vesicle proteins and immuno-
precipitated proteins are detailed in Section 2. a: Blots of sarcolemmal vesicle proteins separated in 10% polyacrylamide gels were probed with
antibodies against caveolin-1, caveolin-2, and caveolin-3 or NXC1 as indicated. All three caveolin isoforms were present in the vesicle prepara-
tions; however, the observed level of caveolin-2 was low. b^d: Blots of immunoprecipitated proteins. Detergent-solubilized BSl proteins were
incubated with Sepharose bead coupled non-immune antibody (b), anti-NCX1 antibody (c) or anti-caveolin-3 antibody (d). Blots were then
probed with anti-caveolin-1, anti-caveolin-2, and anti-caveolin-3 antibodies or anti-NXC1 antibody as indicated. For (c), six-fold more sample
was loaded on gels to visualize NCX1 compared to the sample volume used to visualize caveolin-3.
FEBS 25703 21-1-02
J. Bossuyt et al./FEBS Letters 511 (2002) 113^117114
All three caveolin isoforms were present in BSl vesicles
although caveolin-2 was barely detectable. These were also
observed in sarcolemmal membrane vesicles from canine and
porcine myocardium (not shown). No labeling was observed
when blots were probed with non-immune antibodies (not
shown). The myocardial tissue used to prepare the membranes
is comprised of myocyte, smooth muscle, and endothelial
cells. Much or all of caveolin-1 and -2 may be from endothe-
lial cells, as it has been reported that di¡erentiated muscle
cells mainly express caveolin-3 [14].
3.3. Gradient fractionated myocardial membranes
The ‘standard’ sarcolemmal vesicle preparation [9] uses a
single sucrose step gradient to separate the lighter plasma
membrane fractions from other, higher density cellular mem-
branes. We further fractionated the light membrane fraction
using a multi-step gradient previously reported to fractionate
caveolar proteins [10] (Fig. 3). The peak of NCX1 and cav-
eolin-3 protein tended to co-localize more closely in fractions
3 and 4, while caveolin-1 protein peaked in fractions 4 and 5.
This suggests that NCX1 and caveolin-3 may reside in the
same light membrane fraction while caveolin-1 appears to
be in slightly higher density membranes. The same result,
i.e. the co-fractionation of NCX1 and caveolin-3, was ob-
served on gradients containing total cellular (soluble and
membrane) protein (not shown). It is likely that caveolae
with either caveolin-3 or -1 arise from di¡erent cell types
(myocytes and endothelial cells, respectively).
3.4. Co-precipitation of caveolin-3 and NCX1
To address the question as to which, if any, of the caveolin
protein isoforms associate with NCX1, co-immunoprecipita-
tion experiments were performed. Sepharose beads coupled to
monoclonal antibodies against NCX1, caveolin-3 or non-im-
munogenic IgG were incubated with detergent-extracted sar-
colemmal proteins. The beads were extensively washed with
the extraction bu¡er to remove non-speci¢cally associated
protein. The immunoprecipitate was subjected to Western
blot analysis. The caveolin isoforms and NCX1 did not
non-speci¢cally precipitate with control IgG (Fig. 2b). In
Fig. 2c the presence of NCX1 and caveolin-3 was detected
following precipitation with NCX1 antibody. Caveolin-1 and
-2, while present in the sarcolemmal vesicle membrane prep-
arations (Fig. 2a), did not co-immunoprecipitate with NCX1.
NCX1 and caveolin-3 were detected following precipitation
with immobilized anti-caveolin-3 (Fig. 2d). The results shown
in Fig. 2b^d suggest that cardiac NCX1 speci¢cally associates
with caveolin-3, which is the muscle speci¢c caveolin isoform.
Fig. 3. Sucrose gradient analysis of bovine myocardial membranes.
A crude membrane homogenate of bovine myocardial membranes
was prepared as described in Section 2. Upper: Sucrose density gra-
dient fractions 1^9 as labeled were subjected to Western blot analy-
sis. Lower: Coomassie blue-stained protein pattern of the same gra-
dient fractions.
Fig. 4. Molecular sieve column chromatography fractionation of detergent-solubilized BSl vesicles. Detergent-solubilized BSl proteins were frac-
tionated by molecular sieve column chromatography (Section 2 and as previously described [11]). Shown is the protein elution pro¢le as visual-
ized by Coomassie blue staining (top) and Western blot analysis of the fractions by anti-NCX1 and anti-caveolin-3 antibodies. Column frac-
tions are numbered on the top. Calibration of the column indicated the void volume as fraction 4. NCX1 was detected in fractions 8^10,
which were also the peak fractions for 120 kDa aldolase (from the commercial calibration kit). The results shown are representative of data ob-
tained from two separate molecular sieve columns.
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3.5. Molecular sieve column chromatography fractionation of
BSl vesicle proteins
To exclude the possibility that the co-precipitations (Fig. 2)
are due to the presence of the remnants of lipid raft micro-
domains, we fractionated detergent-solubilized protein by mo-
lecular sieve column chromatography. The column matrix uti-
lized in these experiments excluded proteins or complexes (like
large lipid raft microdomains) greater than 300 kDa. NCX1
was not observed in the void volume fractions but rather
eluted with proteins in the size range included by the column
matrix (Fig. 4). This suggests that NCX1 was completely solu-
bilized by the detergent treatment and not part of a lipid raft
microdomain. Caveolin-3 was observed in many fractions as
expected because it binds to signaling proteins of di¡erent
sizes. It has also been reported that in the presence of octyl-
glucoside, caveolin monomers can form oligomers as large as
350 kDa [15].
3.6. Cholesterol depletion of caveolae and co-precipitation
Functional and structural integrity of caveolae is dependent
upon a critical level of cholesterol in the plasma membrane
and the caveolae itself [2,16]. L-Cyclodextrin, by binding cho-
lesterol, has been shown to disrupt function and structure of
caveolae [16]. The disappearance of caveolae occurs because
caveolin protein requires cholesterol to remain in the mem-
brane [15,16]. Without caveolin protein in the membrane mi-
crodomain, caveolae cannot retain structural integrity. BSl
vesicles were treated with 0.2 and 2.0% (w/v) cyclodextrin
for 1 h on ice prior to solubilization and immunoprecipitation
with immobilized NCX1 antibody. In the same vesicles, L-
cyclodextrin diminished the level of caveolin-3 that co-precipi-
tated with NCX1, while the level of NCX1 was not a¡ected
(Fig. 5a). Densitometric analysis indicated that caveolin-3 co-
precipitation was reduced by 42 and 54% for 0.2 and 2.0% L-
cyclodextrin, respectively. These data suggest that NCX1 and
caveolin-3 are likely inserted in a lipid bilayer with cholesterol
and that cholesterol may be required for the NCX1/caveolin-3
interaction. In other experiments, NCX1 transport activity
was evaluated in BSl vesicles preincubated with L-cyclodextrin
(Fig. 5b). A dose-dependent decrease of NCX1 transport ac-
tivity was observed which paralleled the decrease in co-pre-
cipitated caveolin-3 shown in Fig. 5a. In both experiments,
even at the highest concentration of L-cyclodextrin (2%), co-
precipitation of caveolin-3 and NCX1 activity were dimin-
ished but not abolished. Passive 45Ca2 equilibration in
vesicles treated with L-cyclodextrin was not di¡erent from
control (untreated) vesicles, indicating that this treatment
did not cause these vesicles to become leaky.
In this report, we describe the association of NCX1 with the
muscle speci¢c caveolin isoform, caveolin-3. While all three
known isoforms of caveolin protein are present in cardiac
sarcolemmal vesicle membrane preparations, only caveolin-3
co-precipitates with NCX1. NCX1 can also be co-precipitated
with immobilized caveolin-3 antibody. The low level of NCX1
observed in anti-caveolin-3 precipitations likely re£ects the
ability of caveolin-3 to associate with a wide variety of pro-
teins besides NCX1. In other words, NCX1 may exclusively
associate with caveolin-3, while caveolin-3 can potentially
bind to many di¡erent proteins within caveolae [1,2]. These
observations strongly implicate the presence and partitioning
of some NCX1 protein in myocyte caveolae. In light of recent
reports indicating increased caveolin-3 and NCX1 protein in
HF, it is possible that the increased expression of these two
proteins may not be casually unrelated events [3^7]. Concen-
tration of NCX1 in caveolae has potential rami¢cations in
terms of exchanger function beyond Ca2 homeostasis in my-
ocardial contractility. In cardiac myocytes, it remains to be
shown if NCX1 has additional functions beyond cytosolic
Ca2 homeostasis related to contractility, but the possibility
is intriguing.
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